Iradimed CORP

Iradimed Corporation announced its second quarter 2026 financial results, reporting revenue of $20.5 million and declaring a quarterly cash dividend of $0.20 per share.

Iradimed Corporation stockholders re-elected all board members, ratified the independent auditor, and approved executive compensation at the 2026 Annual Meeting.

IRADIMED CORPORATION announced record fourth quarter and full year 2025 financial results, including significant revenue and EPS growth, and increased its quarterly cash dividend to $0.20 per share.

IRADIMED Corporation announced a special cash dividend of $0.50 per share, payable on December 30, 2025, reflecting strong financial performance and excess cash.

IRADIMED Corporation announced record third-quarter 2025 financial results, including a 16% revenue increase, and raised its full-year guidance, alongside declaring a quarterly cash dividend.

IRADIMED Corporation announced the retirement of director Anthony Vuoto and the appointment of medical technology innovator Joe Kiani to its Board of Directors.

IRadimed Corporation announced its second quarter 2026 financial results, showing a slight increase in revenue and a decrease in net income compared to the prior year period.

IRADIMED Corporation reported a strong third quarter 2025 with revenue increasing 16% to $21.2 million and diluted EPS rising to $0.43, driven by demand for MRI-compatible medical devices.

IRADIMED Corporation announced robust financial results for Q2 2025, driven by increased domestic sales and the recent FDA clearance of its next-generation MRidium 3870 IV infusion pump system.

IRADIMED Corporation announces an 11% increase in revenue for the first quarter of 2025, fueled by robust sales of its MRI compatible medical devices and related products.

IRADIMED Corporation's Q3 2024 results show an 11% increase in revenue compared to the same period last year, driven by strong demand for its MRI compatible medical devices.

IRADIMED Corporation's Q2 2024 revenue increased by 11.2% year-over-year, driven by strong sales of its MRI compatible medical devices.

IRadimed Corporation announced robust financial results for fiscal year 2025, driven by increased sales of its MRI-compatible medical devices and the launch of its new MRidium 3870 IV infusion pump system.

IRADIMED Corporation filed an amended annual report for 2024, correcting a certification omission while reporting significant revenue and profit growth driven by domestic sales.

IRADIMED Corporation's 2024 annual report reveals a 12% increase in revenue, reaching $73.2 million, driven by growth in MRI compatible medical device sales.

IRADIMED Corporation's 2023 annual report reveals a significant increase in revenue and profitability, driven by strong sales of its MRI compatible medical devices.

Director Hilda Scharen-Guivel of IRADIMED CORPORATION sold 3,000 shares of common stock at a price of $95.00 per share.

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling 2,669 shares, executed under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corporation CEO Roger E. Susi sold 7,500 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp CEO Roger E. Susi reported the sale of common stock totaling over 6,000 shares across multiple transactions executed between May 18-19, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp CEO Roger E. Susi sold a total of 6,486 shares of common stock across multiple transactions on May 11th and 12th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp's CEO, Roger E. Susi, reported the sale of common stock totaling 7,527 shares across multiple transactions executed between May 4th and May 5th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corporation has scheduled its 2025 Annual Meeting of Stockholders for June 19, 2025, to elect directors, ratify the appointment of its independent accounting firm, and conduct an advisory vote on executive compensation.

IRADIMED Corporation files a supplement to its definitive proxy statement to correct an incorrect date related to security ownership information.

IRADIMED Corporation will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, to elect directors, ratify the appointment of its independent accounting firm, and approve executive compensation.

Roger E. Susi and associated family trusts report a combined 34.8% beneficial ownership stake in Iradimed Corporation.

Nine Ten Capital Management and affiliates reported a 3.4% beneficial ownership stake in iRadimed Corp, holding 428,477 common shares.

BlackRock, Inc. has filed an Amendment No. 2 to its Schedule 13G, disclosing a passive beneficial ownership of 3.9% in IRADIMED CORP's common stock as of March 31, 2025.

Nine Ten Capital Management, along with Nine Ten Partners LP and Russell Mollen, has disclosed a beneficial ownership of 7.1% in iRadimed Corp's common stock.